During the analysis, investigators found that the frequency of BRCA2 and other HRR alterations in mHSPC was comparable with what has been observed in metastatic castration-resistant prostate cancer (mCRPC), Olmos said. The proportion of germline vs somatic mutations was also similar to mCRPC, although there was a slightly higher rate of germline BRCA2 alterations in the patients with mHSPC. This observation is consistent with prior reports linking germline BRCA2 mutations to an increased risk of metastatic spread at presentation, he noted. From an efficacy perspective, the study reinforced the prognostic effect of BRCA1 and BRCA2 alterations, Olmos explained. Olmos emphasized that these results highlight the importance of early molecular profiling in metastatic disease.